The persistence of LSCs is clinically reflected by residual BCR::ABL1-expression in CML patients in major or deep molecular response (MMR, DMR), which often persist at a very low level despite long-term treatment. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.